Stage IVC Squamous Cell Carcinoma of the Oropharynx Completed Phase 2 Trials for Cetuximab (DB00002)

IndicationStatusPhase
DBCOND0029839 (Stage IVC Squamous Cell Carcinoma of the Oropharynx)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00939627Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent CetuximabTreatment